British Guidelines for Testosterone Replacement Therapy
The most authoritative British guidance comes from the British Society for Sexual Medicine (BSSM) 2017 guidelines, which recommend testosterone replacement therapy for symptomatic men with confirmed biochemical testosterone deficiency (total testosterone <12 nmol/L or <350 ng/dL on two morning samples), with the primary goal of improving sexual function, body composition, mood, and bone health while carefully monitoring for adverse effects 1.
Diagnostic Criteria
The BSSM guidelines establish clear diagnostic thresholds:
- Biochemical confirmation required: Two morning fasting total testosterone measurements below 12 nmol/L (350 ng/dL) 1, 2
- Symptomatic presentation mandatory: Low testosterone alone without symptoms does not warrant treatment
- Key symptoms to assess: Sexual dysfunction (reduced libido, erectile dysfunction), fatigue, mood disturbances, reduced muscle mass, and decreased bone density 1
The British approach differs slightly from American guidelines by setting a unified threshold at 12 nmol/L rather than the variable 300-350 ng/dL range, providing clearer decision-making for UK practitioners 1.
Initiating Treatment
Target testosterone levels in the mid-normal range (450-600 ng/dL or 15.6-20.8 nmol/L) to optimize symptom improvement while minimizing adverse effects 3.
Available Formulations (UK-specific considerations):
- Transdermal gels: First-line in UK practice; assess levels after 1 week of treatment
- Injectable testosterone undecanoate: Widely available in UK; measure levels just prior to next injection
- Transdermal patches: Assess 3-12 hours post-application
- Testosterone pellets: Available in UK; measure at end of dosing interval
The British guidelines emphasize using commercially manufactured products over compounded preparations due to quality control concerns 4.
Monitoring Protocol
The BSSM and UK consensus recommend structured follow-up 1, 5:
Initial Phase (First 3-6 months):
- Clinical assessment at 3 months: Evaluate symptom response and adverse effects 3
- Testosterone level at 3 months: Adjust dose to achieve mid-normal range
- Hematocrit at 3 months: Critical safety parameter
- PSA and digital rectal examination at 3 months (for men ≥40 years with baseline PSA >0.6 ng/mL) 3
Maintenance Phase (After 6 months):
- Annual clinical review: Assess ongoing symptom control and quality of life 5
- Testosterone levels every 6-12 months 4, 5
- Annual hematocrit monitoring 3
- PSA monitoring: Follow age-appropriate prostate cancer screening guidelines 3
- Bone mineral density: After 1-2 years in men with osteoporosis or low-trauma fracture 3
Critical Safety Thresholds:
Stop therapy immediately if hematocrit exceeds 54% 3. Evaluate for hypoxia and sleep apnea before reinitiating at reduced dose. This is a firm safety boundary, not a suggestion.
Obtain urgent urology referral if 3:
- PSA increases >1.4 ng/mL within any 12-month period
- PSA velocity >0.4 ng/mL/year (after 6 months of therapy)
- Palpable prostate abnormality on examination
- Lower urinary tract symptoms score >19
Absolute Contraindications
The British guidelines align with international consensus on contraindications 6, 1:
- Active prostate or breast cancer
- Palpable prostate nodule or PSA >4 ng/mL without urological evaluation
- Planning fertility in near term (testosterone suppresses spermatogenesis)
- Hematocrit >50% at baseline
- Untreated severe obstructive sleep apnea
- Uncontrolled heart failure
- Myocardial infarction or stroke within 6 months
- Severe lower urinary tract symptoms
Special Populations
Men Desiring Fertility:
Do not use testosterone therapy. Instead, consider alternatives that preserve spermatogenesis 4:
- Human chorionic gonadotropin (hCG) - only FDA-approved option for males
- Selective estrogen receptor modulators (clomiphene citrate)
- Aromatase inhibitors
Note that only hCG has regulatory approval for male use; others are off-label 4.
Men with Prostate Cancer History:
Recent British consensus (2025) suggests TRT may be considered in carefully selected men post-radical prostatectomy or post-radiotherapy with undetectable PSA, but requires multidisciplinary discussion and intensive monitoring 7. This represents evolving practice beyond traditional absolute contraindication.
Key British Practice Points
The UK implementation differs from other guidelines in several practical aspects:
Recall systems: British practices successfully use existing chronic disease recall systems (similar to diabetes monitoring) to achieve >60% compliance with annual monitoring 5
Primary care involvement: UK guidelines explicitly encourage GP management of uncomplicated cases, with specialist referral reserved for complex situations 2
Standardized blood test panels: Use of electronic order templates (Ordercomms blood group templates) improves monitoring consistency 5
Patient education: Provision of standardized patient information leaflets improves adherence to monitoring schedules 5
Common Pitfalls to Avoid
Do not treat based on single testosterone measurement - always confirm with second morning sample 1. Testosterone levels fluctuate significantly, and false-positive diagnoses lead to unnecessary lifelong therapy.
Do not ignore hematocrit monitoring - this is the most common serious adverse effect and requires immediate action at >54% 3. Failure to monitor has led to thromboembolic events.
Do not continue therapy without symptom improvement - if target testosterone levels are achieved at 3-6 months but symptoms persist, discontinue therapy and investigate alternative causes 4. There is no benefit to maintaining supraphysiologic testosterone in non-responders.
Do not use testosterone in men actively trying to conceive - this will suppress fertility and may take 6-12 months to reverse after discontinuation 6, 4.
Cardiovascular Safety
Recent large trials (TRAVERSE) have clarified that testosterone therapy does not increase major adverse cardiovascular events, though mild increases in systolic blood pressure may occur 8. The 2025 EAU guidelines and FDA labeling reflect this updated safety profile, supporting the British approach of careful cardiovascular risk factor management alongside TRT 8.